This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Explore Oncology Resources | PP-PF-ONC-GB-0411, February 2024

Oncology
nmCRPC Patient Case Study
NUBEQA® (darolutamide) - A Urologist Perspective
PP-NUB-GB-2038, January 2025
nmCRPC Patient Case Study
NUBEQA® (darolutamide) - A Clinical Nurse Specialist Perspective
PP-NUB-GB-2046, January 2025
nmCRPC Patient Case Study
NUBEQA® (darolutamide) - A Pharmacist Perspective
PP-NUB-GB-2028, January 2025
nmCRPC Patient Case Study
NUBEQA® (darolutamide) - An Oncologist Perspective
PP-NUB-GB-2031, January 2025
Xofigo®▼ (radium-223 dichloride) Resources
PP-XOF-GB-0580, August 2024
mCRPC Patient Case Study
A Nuclear Medicine perspective - Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0575, June 2024
mCRPC Patient Case Study
An Oncologist Perspective - Xofigo®▼ (radium-223 dichloride)
PP-XOF-GB-0574, June 2024
HCC Resources
Nexavar® (sorafenib) | Stivarga® (regorafenib)